CING

Cingulate Inc.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001862150 Biotech & Drug Discovery

$4.98 +0.32 (+6.87%)

Oct 23 4:00 PM ET · prev $4.66

Market cap

$67.8M

Micro cap

Consensus

Buy

90% Buy or better · 10 analysts

Median target

🔒 Subscribers only

1 year

+29.0%

from $3.86 · Oct 24

30 days

−1.6%

from $5.06

52-week range

$3.33–11.66

−57% from high · low Nov 13

Avg volume 20D

96.8K

shares / day

Short interest

1.03M

≈7.1% of shares · −11.9%

Days to cover

10.5

at average volume

Insider net

+$667.4K

5 buyers · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 3 reports · 90 days

Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score

Avg score

·High conf. 2/3

Strongest NEUTRAL Cingulate Inc. filed an 8-K to disclose an amendment to the employment agreement of its Chief Medical…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Feb 6 to Feb 13 2 days of insider buys: $667.4K by 5 insiders, avg $2.84
E May 31 FDA decision: PDUFA: CING — CTx-1301 in ADHD — 2026-05-31
R Jun 16 Cingulate announced the USPTO issued its first company-owned U.S. pa…

Signal stack

Where each data set points today.

InsidersBULLISH

5 insiders bought $667.4K at an average $2.84. No open-market sales. Price is 75% above their cost.
InstitutionsBULLISH

Q2 2026: 11 added (0 new), 1 trimmed or exited.
AnalystsBULLISH

9 of 10 rate it Buy or better.
Short sellersSTEADY

Short interest −11.9% to 1.03M shares. 10.5 days to cover, ≈7.1% of shares.
TrendDOWNTREND

1% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
VANGUARD CAPITAL MANAGEMENT LLC	ADD	570,873	$3.1M
GEODE CAPITAL MANAGEMENT, LLC	ADD	144,636	$791.4K
RENAISSANCE TECHNOLOGIES LLC	DOUBLED	127,500	$697.4K
VANGUARD FIDUCIARY TRUST CO	ADD	79,160	$433.0K
BlackRock, Inc.	DOUBLED	53,130	$290.6K
STATE STREET CORP	ADD	47,888	$261.9K
NORTHERN TRUST CORP	ADD	35,121	$192.1K
JANE STREET GROUP, LLC	TRIM	28,878	$158.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts

Buy 90% rate it Buy or better

Strong Buy2Buy7Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access

Recent actions

Date	Firm	Action	Rating
Aug 24, 2026	Roth Capital REITERATE	REITERATE	Buy
Aug 20, 2026	Ascendiant Capital MAINTAIN	MAINTAIN	Buy
Jun 8, 2026	Ascendiant Capital MAINTAIN	MAINTAIN	Buy
May 26, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy

Insider ledger

Form 4

$667.4K

bought · 5 insiders

sold · 0 insiders

+75.1%

vs their $2.84 cost

Date	Insider	Type	Value
Sep 30, 2026	Silva Raul R. EVP and CSO	AWARD	4,293 sh
Jul 16, 2026	Hargroves Thomas Jeffrey Director	AWARD	20,000 sh
Jul 16, 2026	Werth Peter J. Director	AWARD	20,000 sh
Jul 16, 2026	Silva Raul R. EVP and CSO	AWARD	26,400 sh
Jul 16, 2026	Lawrence Bryan Jay Director	AWARD	20,000 sh
Jul 16, 2026	Downey Bryan Wade EVP & Chief Commercial Officer	AWARD	33,000 sh
Jul 16, 2026	Schaffer Shane J. Chief Executive Officer	AWARD	197,650 sh
Jul 16, 2026	Schaffer Shane J. Chief Executive Officer	AWARD	97,350 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

Period	EPS est.	Range	30D rev.	Revenue
Current Q	🔒 Fresh data — subscribers only
Next Q	🔒 Fresh data — subscribers only
Current FY	🔒 Fresh data — subscribers only
Next FY	🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026

1,031,388

shares short

-11.9%

vs prior settlement

10.5

days to cover

≈7.1%

of shares outstanding

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 2, 2026 SEC

Cingulate Inc. filed an 8-K to disclose an amendment to the employment agreement of its Chief Medical Officer, Matthew…

8-K — Impact 3/10

Sep 30, 2026 Insider

Silva Raul R. was granted 4,293 shares

EVP and CSO

Sep 22, 2026 SEC

A cluster of 9 institutional investors accumulated $2.3M in Cingulate Inc. during Q2 2026, while only one firm…

INST-CLUSTER — Impact 3/10

Sep 17, 2026 Other

Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma

Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for

Aug 13, 2026 SEC

Cingulate reported Q2 2026 financial results with a net loss of $5.9M, widening from $5.0M a year ago, as SG&A…

8-K — Impact 4/10

Jul 16, 2026 Insider

Hargroves Thomas Jeffrey was granted 20,000 shares

Director

Jul 16, 2026 Insider

Werth Peter J. was granted 20,000 shares

Director

Jun 30, 2026 Inst.

VANGUARD CAPITAL MANAGEMENT LLC — ADD

570,873 shares ($3.1M)

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Recent

Sep 17, 2026

Press release

Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma

Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size Pharma Chief Commercial…

Aug 14, 2026

Short interest

Short Interest: CING down 23% to 1.2M shares

Settlement 2026-08-14 | Days to cover: 7.80 | ≈8.27% of shares outstanding (est.)

Aug 13, 2026

Earnings

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Cash and Cash Equivalents of $28.4 Million as of June 30, 2026 Providing Runway Through Mid-2027; Company Advances Chemistry, Manufacturing and…

Jul 15, 2026

Short interest

Short Interest: CING up 22% to 1.7M shares